Janssen JAMJL - Search Results

1

Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years.

van Santen SS, Olsson DS, van den Heuvel-Eibrink MM, Wijnen M, Hammarstrand C, Janssen JAMJL, Johansson G, van der Lely AJ, Neggers SJCMM. van Santen SS, et al. Among authors: janssen jamjl. J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1397-407. doi: 10.1210/clinem/dgz279. J Clin Endocrinol Metab. 2020. PMID: 32145029 Free PMC article.

2

IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly.

de Herder WW, van der Lely AJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW. de Herder WW, et al. Clin Endocrinol (Oxf). 1995 Oct;43(4):501-5. doi: 10.1111/j.1365-2265.1995.tb02623.x. Clin Endocrinol (Oxf). 1995. PMID: 7586626

3

Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus.

Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW. Janssen JA, et al. J Clin Endocrinol Metab. 1997 Sep;82(9):2809-15. doi: 10.1210/jcem.82.9.4180. J Clin Endocrinol Metab. 1997. PMID: 9284701 Free article.

4

Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis.

van der Lely AJ, de Herder WW, Janssen JA, Lamberts SW. van der Lely AJ, et al. J Endocrinol. 1997 Oct;155 Suppl 1:S9-13; discussion S15-6. J Endocrinol. 1997. PMID: 9389990

5

Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels.

Janssen JA, Stolk RP, Pols HA, Grobbee DE, de Jong FH, Lamberts SW. Janssen JA, et al. Clin Endocrinol (Oxf). 1998 Apr;48(4):471-8. doi: 10.1046/j.1365-2265.1998.00300.x. Clin Endocrinol (Oxf). 1998. PMID: 9640414

6

Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women.

Janssen JA, Burger H, Stolk RP, Grobbee DE, de Jong FH, Lamberts SW, Pols HA. Janssen JA, et al. Eur J Endocrinol. 1998 Jun;138(6):627-32. doi: 10.1530/eje.0.1380627. Eur J Endocrinol. 1998. PMID: 9678528 Free article. Clinical Trial.

7

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW. van der Lely AJ, et al. J Clin Endocrinol Metab. 2001 Feb;86(2):478-81. doi: 10.1210/jcem.86.2.7206. J Clin Endocrinol Metab. 2001. PMID: 11157994 Free article.

8

Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.

Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ. Muller AF, et al. J Clin Endocrinol Metab. 2001 Feb;86(2):590-3. doi: 10.1210/jcem.86.2.7173. J Clin Endocrinol Metab. 2001. PMID: 11158013 Free article.

9

[Growth hormone receptor antagonists: potential indications].

Muller AF, Janssen JA, de Herder WW, van der Lely AJ. Muller AF, et al. Ned Tijdschr Geneeskd. 2001 Jan 13;145(2):69-73. Ned Tijdschr Geneeskd. 2001. PMID: 11225259 Review. Dutch.

10

Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.

Muller AF, Janssen JA, Lamberts SW, Bidlingmaier M, Strasburger CJ, Hofland L, van der Lely AJ. Muller AF, et al. Clin Endocrinol (Oxf). 2001 Oct;55(4):461-7. doi: 10.1046/j.1365-2265.2001.01374.x. Clin Endocrinol (Oxf). 2001. PMID: 11678828 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters